Antiviral and antiretroviral use in pregnancy

Obstetrics and Gynecology Clinics of North America

Volumn 30, Issue 4, 2003, Pages 731-749

  Money, Deborah M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; ALPHA INTERFERON; AMANTADINE; AMPRENAVIR; ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; OSELTAMIVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RIMANTADINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SIALIDASE INHIBITOR; STAVUDINE; UNINDEXED DRUG; VALACICLOVIR; ZALCITABINE; ZANAMIVIR; ZIDOVUDINE;

ABDOMINAL DISCOMFORT; ANOREXIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARDIOMYOPATHY; CARDIOVASCULAR MALFORMATION; CLINICAL TRIAL; CONFUSION; CONGENITAL MALFORMATION; DEPRESSION; DIARRHEA; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; EMBRYOTOXICITY; FATTY LIVER; FETOTOXICITY; FEVER; GASTROINTESTINAL SYMPTOM; GENITAL ULCER; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFLUENZA VIRUS A; INSOMNIA; LACTIC ACIDEMIA; LEUKOPENIA; MALAISE; MEGALOCYTOSIS; MITOCHONDRIAL TOXICITY; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PREGNANCY COMPLICATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RASH; RESPIRATORY DISTRESS; REVIEW; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THOUGHT DISORDER; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

EID: 0346992218     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(03)00089-5     Document Type: Review

References (124)

1. Beckman DA, Brinkman K. Mechanism of known environmental teratogens: drugs and chemicals. Clin Perinatol 1986;13:649-87.
2. Hay AJ, Wolstenhome AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985;4:3021-4.
3. Zyldnikov DM, Kubar OI, Kovaleva TP, Kamforin LE. Study of rimantadine in the USSR: a review of the literature. Rev Infect Dis 1981;3:408.
4. Hirsch MS, Swartz MN. Drug therapy: antiviral agents (first of two parts). N Engl J Med 1980;302(16):903-7.
5. th edition. Montvale (NJ): Medical Economics Co.; 2000. p. 1040.
6. th edition. Montvale (NJ): Medical Economics Co.; 2000. p. 1078.
7. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000;355:827.
8. Wenzel RP. Expanding the treatment options for influenza. JAMA 2000;283:1057.
9. Dunn CJ, Goa KL. Zanamivir: a review of its use in influenza. Drugs 1999;58:761.
10. Bardsley-Elliot A, Noble S. Oseltamivir. Drugs 1999;58:851.
11. Roche Laboratories. Tamiflu [package insert]. Nutley (NJ): Roche Laboratories; 1999.
12. Glaxo Wellcome. Relenza (zanamivir for inhalation) [package insert]. Research Triangle Park (NC): Glaxo Wellcome; 2000.
13. Stagno S. Cytomegalovirus. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. 5th edition. Philadelphia: WB Saunders Company; 2001. p. 389.
14. Laerum OD. Toxicology of acyclovir. Scand J Infect Dis Suppl 1985;47:40-3.
15. Cole NL, Balfour HH. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987;6:255-61.
16. Hirsch MS, Swartz MN. Drug therapy: antiviral agents (second of two parts). N Engl J Med 1980;302(17):949-53.
17. Broussard RC, Payne DK, George RB. Treatment with acyclovir of varicella pneumonia in pregnancy. Chest 1991;99(4):1045-7.
18. Cox SM, Cunningham FG, Luby J. Management of varicella pneumonia complicating pregnancy. Am J Perinatol 1990;7(4):300-1.
19. Lotshaw RR, Keegan JM, Gordon HR. Parenteral and oral acyclovir for management of varicella pneumonia in pregnancy: a case report with review of literature. W V Med J 1991;87(5):204-6.
20. Mutalik S, Gupte A, Gupte S. Oral acyclovir therapy for varicella in pregnancy. Int J Dermatol 1997;36(1):49-51.
21. Braig S, Luton D, Sibony O, Edlinger C, Boissinot C, Blot P, et al. Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding. Eur J Obstet Gynecol Reprod Biol 2001;96(1):55-8.
22. Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD. Acyclovir suppression to prevent recurrent genital herpes at delivery. Infect Dis Obstet Gynecol 2002;10(2): 71-7.
23. Brocklehurst P, Kinghorn G, Carney O, Helsen K, Ross E, Ellis E, et al. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynaecol 1998;105(3):275-80.
24. Watts DH, Brown ZA, Money D, Selke S, Huang ML, Sacks SL, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol 2003;188(3):836-43.
25. Kimberlin DF, Weller S, Whitley RJ, Andrews WW, Hauth JC, Lakeman F, et al. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am J Obstet Gynecol 1998;179:846-51.
26. Andrews EB, Yankaskas BC, Cordero JF, Schoeffler K, Hampp S. Acyclovir in pregnancy registry: six years' experience. The Acyclovir in Pregnancy Registry Advisory Committee. Obstet Gynecol 1992;79(1):7-13.
27. Nicholson KG. Properties of antiviral agents. Lancet 1984;2(8401):503-6.
28. Dekker CL, Prober CG. Pediatric uses of valacyclovir, penciclovir and famciclovir. Pediatr Infect Dis J 2001;20(11):1079-81.
29. Feinberg JE, Hurwitx S, Cooper D, et al. A randomized, double-blind trial of valacyclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis 1998;177:48.
30. Perry CM, Wagstaff AJ. Famciclovir: a review of its pharmacologic properties and therapeutic efficacy in herpesvirus infections. Drugs 1995;50:396.
31. Sacks SL, Bishop AM, Fox R, Lee GCY. A double-blind, placebo (PLB)-controlled trial of the effect of chronically administered oral famciclovir (FCV:BRL 42810) on sperm production in men with recurrent genital herpes (RGH) infection. Antiviral Res 1994;23:72.
32. Faulds D, Heel RC. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990;39:597-638.
33. Markam A, Faulds D. Ganciclovir: an update of its therapeutic use in cytomegalovirus infection. Drugs 1994;48:455-84.
34. Chahoud I, Bochert G, Stahlmann R. Teratogenic effects of ganciclovir in rats. Teratology 2003;55:40.
35. Hartmann J, Chahoud I, Buerkle B, Neubert D. Testis hypoplasia in rat offspring prenatally exposed to ganciclovir. Teratology 1991;44:25A.
36. Pescovitz MD. Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient. Transplantation 1999;67:758-9.
37. Gilstrap LC, Bawdon RE, Roberts SW, Sobhi S. The transfer of the nucleoside analog ganciclovir across the perfused human placenta. Am J Obstet Gynecol 1994;170:967-73.
38. Whitley RJ, Cloud G, Gruber W, Storch GA, Demmler GJ, Jacobs RF, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997;175:1080-6.
39. Food and Drug Administration. Ribavirin aerosol approved for severe cases of RSV in infants and young children. FDA Drug Bulletin 1986;16:7.
40. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13): 975-82.
41. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65.
42. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801-9.
43. Fenn VH, Willhite CC, Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 1978;17:93-102.
44. Kilham L, Ferm VH. Congenital anomalies induced in hamster embryos with ribavirin. Science 1977;195:551-61.
45. Atmar RL, Englund JA, Hammill H. Complications of measles during pregnancy. Clin Infect Dis 1992;14:217-26.
46. Flint AP, et al. A role of interferons in the maternal recognition of pregnancy. Mol Cell Endocrinol 1988;58:109-11.
47. Mubarak AA, Kakil IR, Awidi A, Al Homsi U, Fawzi Z, Kelta M, et al. Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1st trimester: report of 3 cases and review of the literature. Am J Hematol 2002;69(2):115-8.
48. Ozaslan E, Yilmaz R, Simsek H, Tatar G. Interferon therapy for acute hepatitis C during pregnancy. Ann Pharmacother 2002;36(11):1715-8.
49. Mannering GJ, Deloria LB. The pharmacology and toxicology of the interferons. Annu Rev Pharmacol Toxicol 1986;26:455-515.
50. Vilcek J. Adverse effects of interferon in virus infections, autoimmune diseases and acquired immunodeficiency. Prog Med Virol 1984;30:62-77.
51. Hiratsuka M, Minakami H, Koshizuka S, Sato I. Administration of interferon-alpha during pregnancy: effects on fetus. J Perinat Med 2000;28(5):372-6.
52. Trotter JF, Zygmunt AJ. Conception and pregnancy during interferon-alpha therapy for chronic hepatitis C. J Clin Gastroenterol 2001;32(1):76-8.
53. Maurice-Estepa L, Daudon M, Kalama C, Jouanneau C, Sazdovitch V, Lacour B, et al. Identification of crystals in kidneys of AIDS patient treated with foscamet. Am J Kidney Dis 1998;32:392-400.
54. Wagstaff AJ, Bryson HM. Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994;48:199-226.
55. Caracatsanis M, Fouda N, Hammarstrom L. Effects of phophonoformic and phophonoacetic acids on developing enamel of rat molars. Scand J Dent Res 1989;97:139-49.
56. Alvarez-McLeod A, Havlik J, Drew KE. Foscarnet treatment of genital infection due to acyclovir-resistant herpes simplex virus type 2 in a pregnant patient with AIDS: case report. Clin Infect Dis 1999;29(4):937-8.
57. UNAIDS/WHO. Joint United Nations programme on HIV/AIDS: AIDS epidemic update. Geneva: WHO; 2002.
58. Bureau of HIV/AIDS and STD. HIV in Canada: surveillance report. Ottawa, Canada: Bureau of HIV/AIDS and STD. Laboratory Centre for Disease Control (LCDC), Health Canada; 2001.
59. Dybel M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the panel on clinical practices for treatment of HIV. MMWR Recomm Rep 2002;51(RR-7):1-5.
60. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279(6):450-4.
61. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV outpatient study investigators. N Engl J Med 1998;338(13):853-60.
62. International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta analysis of 15 prospective cohort studies. N Engl J Med 1999;340:977-87.
63. nd Global Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants. Montreal, May 1-4, 1999.
64. Mofenson LM. US Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep 2002;51(RR-18): 1-4.
65. Burdge DR, Money DM, Forbes JC, Walmsley SL, Smaill FM, Boucher M, et al. Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring. CMAJ 2003;168:1671-4.
66. Watts DH. Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002;346:1879-91.
67. Minkoff H. Human immunodeficiency virus infection in pregnancy. Obstet Gynecol 2003;101(4):797-810.
68. Deeks SG. Antiretroviral agents: the next generation. AIDS Clinical Care 1998;10:33-40.
69. Silverman NS, Watts DH, Hitti J, Money DM, Livingston E, Axelrod J, et al. Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy. Infect Dis Obstet Gynecol 1998;6(6):237-43.
70. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-22.
71. Brinkman K, ter Hofstede HJM, Berger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
72. Thompson CA. Antiretroviral combination may put pregnant women at risk of fatal lactic acidosis. Am J Health Syst Pharm 2001;58(4):291.
73. th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, May 7-11, 2002.
74. th Annual Conference of the British HIV Association. Glasgow, Scotland, November, 2001.
75. Giaquinto C, et al. Lactic acid in infants perinatally exposed to antiretrovirals. Presented at the 14th International AIDS Conference. Barcelona, June 25-30, 2002.
76. Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354(9184):1084-9.
77. Conner EM, Sperling RS, Gelber R, Kiselev P, Scott G, O-Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
78. Watts DH, Brown ZA, Tartaglione T. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991;163:226-32.
79. Sperling RS, Roboz J, Dische R, et al. Zidovudine pharmacokinetics during pregnancy. Am J Perinatol 1992;9:247-9.
80. Ferrazin A, De Maria A, Gotta C. Zidovudine therapy of HIV-1 infection during pregnancy: assessment of the effect on the newborns. J Acquir Immune Defic Syndr 1993;6:376-9.
81. Sperling RS, Stratton P, O'Sullivan MJ, et al. A survey of zidovudine use in pregnant women with human immunodeficiency virus infection. N Engl J Med 1992;326:857-61.
82. Frenkel LM, Cowles MK, Shapiro DE, et al. Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997;176(4):971-4.
83. McGowan JP, Crane M, Wiznia AA, Blum S. Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women. Obstet Gynecol 1999;94(5 Pt 1):641-6.
84. Jungmann EM, Mercey D, De Ruiter A, Edwards S, Donoghue S, Booth T, et al. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Infect 2001;77(6):441-3.
85. Toltzis P, Marx CM, Kleinman N, Levine EM, Schmidt EV. Zidovudine-associated embryonic toxicity in mice. J Infect Dis 1991;163(6):1212-8.
86. Anderson JR. AZT carcinogenesis in pregnancy. The Hopkins HIV Report 1997;9:2.
87. Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants. N Engl J Med 2000;343:759-66.
88. Lindegren ML, Rhodes P, Gordon L, Fleming P. Drug safety during pregnancy and in infants: lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann N Y Acad Sci 2000;918:222-35.
89. Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Lecuwen R, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998;178(5):1327-33.
90. Bloom SL, Dias KM, Bawdon R, et al. The maternal-fetal transfer of lamivudine in the ex-vivo human placenta. Am J Obstet Gynecol 2000;176:291-3.
91. Tuntland T, Nosbisch C, Baughman WL, et al. Mechanism and rate of placental transfer of zalcitabine (2′3′-dideoxycytidine) in Macaca nemestrina. Am J Obstet Gynecol 1996;174: 856-63.
92. Odinecs A, Nosbisch C, Keller RD, et al. In vivo maternal-fetal pharmacokinetics of stavudine (2,3-didehydro-3′-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996;40:196-202.
93. Bawdon RE, Kaul S, Sbhi S. The ex vivo transfer of the anti-HIV molecule compound d4T in the human placenta. Gynecol Obstet Invest 1994;38:1-4.
94. Chmait R, Franklin P, Spector SA, Hull AD. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinal 2002;22:370-373.
95. Goldstein PJ, Smit R, Stevens M, Sever JL. Association between HIV in pregnancy and antiretroviral therapy, including protease inhibitors and low birth weight infants. Infect Dis Obstet Gynecol 2000;8:2.
96. Garcia-Tejedor A, Perales A, Maiques V. Protease inhibitor treatment in HIV pregnant women. Is it safe for newborns? Int J Gynaecol Obstet 2002;76(2):175-6.
97. Stek A, Kramer F, Fassett M, Khoury M. The safety and efficacy of protease inhibitor therapy for HIV infection during pregnancy. Am J Obstet Gynecol 1999;180(1 Pt 2):S7.
98. Lorenzi P, Spicher VM, Laubereau B, Hirschel B, Kind C, Rudin C, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998;12(18): F241-7.
99. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002;16(6):889-93.
100. Antiretroviral Pregnancy Registry. International interim report for 1 January 1989-31 July 2002: executive summary. 2003. Available at www.APRegistry.com.
101. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000;14(18):2913-20.
102. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346(24):1863-70.
103. Bawdon RE. The ex vivo human placental transfer of anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir. Infect Dis Obstet Gynecol 1998;6:244-6.
104. Tarantal AF, Castillo A, Ekert JE, et al. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002;29:207-20.
105. Mirochnick M, Simminski S, Fenton T, Lugo M, Sullivan JL. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001;20:803-5.
106. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission to HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354(9181):795-802.
107. Centers for Disease Control and Prevention. Serous adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2003;49(51-52):1153-6.
108. Nightingale SL. From the Food and Drug Administration. JAMA 1998;280:1472.
109. Fundaro C, Genovese O, Rendeli C, et al. Myelomenigocele in a child with intrauterine exposure to efavirenz. AIDS 2002;16:299-300.
110. Hill JB, Sheffield JS, Zeeman GG, Wendel GD. Hepatotoxicity with antiretroviral treatment of pregnant women. Obstet Gynecol 2001;98(5 Pt 2):909-11.
111. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002;78:58-9.
112. th International AIDS Conference. Barcelona, June 30-July 5, 2002.
113. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-94.
114. Goldstein PJ, Smit R, Stevens M, Sever JL. Association between HIV in pregnancy and antiretroviral therapy, including protease inhibitors and low birth weight infants. Infect Dis Obstet Gynecol 2000;8(2):94-8.
115. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001;285:2083-93.
116. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003;33:175-83.
117. Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson M, Erdem G, Pinta M, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003;32:370-4.
118. Bucceri AM, Somigliana E, Matrone R, Ferraris G, Rossi G, Grossi E, et al. Combination antiretroviral therapy in 100 HIV-1-infected pregnant women. Hum Reprod 2002;17:436-41.
119. Clarke SM, Mulcahy F, Healy CM, Condon S, Butler KM. The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome. Int J STD AIDS 2000;11(4):220-3.
120. Grubert TA, Wintergerst U, Lutz-Friedrich R, Belohradsky BH, Rolinski B. Long-term antiretroviral combination therapy including lamivudine in HIV-1 infected women during pregnancy. AIDS 1999;13(11):1430-1.
121. Morris AB, Cu-Uvin S, Harwell JL, Garb J, Zorilla C, Vajaranant M, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr 2000;25:306-11.
122. The European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003;32:380-7.
123. Wimalasundera RC, Larbalestier N, Smith JH, De Ruiter A, McThom SA, Hughes AD, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002;360(9340):1152-4.
124. Mawson AR. Effects of antiretroviral therapy on occurrence of pre-eclampsia. Lancet 2003;361(9354):347-8.